TYNDALL JOSEPH A.

SEC source: 0000805928-26-000101 · wk-form4_1788552483.xml · nonDerivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,650

F1 · kind: The sale reported on the this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on June 3, 2026.

F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $48.01 to $51.46 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-26-000087 · wk-form4_1782507161.xml · derivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,392

Underlying: Common Stock · 4,392 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

F2 · derivative.underlying: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $185,000 valuation as of the grant date and vests on June 24, 2027, the one-year anniversary of the grant date.

SEC source: 0000805928-26-000077 · wk-form4_1782246960.xml · derivative · entry 2

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,150 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

SEC source: 0000805928-26-000077 · wk-form4_1782246960.xml · nonDerivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,150

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested June 19, 2026.

SEC source: 0000805928-25-000166 · wk-form4_1765405243.xml · derivative · entry 6

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,311

Underlying: Common Stock · 10,860 shares

Expires 2032-12-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Option grant for joining the Issuer's Board of Directors. Options vest in three equal annual installments on the annual anniversary of the grant date with the first vesting date occurring on December 13, 2023.

SEC source: 0000805928-25-000166 · wk-form4_1765405243.xml · derivative · entry 5

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,248 shares

Expires 2034-06-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Non-qualified stock option portion of the 2024 annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The grant vested on June 6, 2025, the one-year anniversary of the grant date.

SEC source: 0000805928-25-000166 · wk-form4_1765405243.xml · nonDerivative · entry 4

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $30.485 to $31.305 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-25-000166 · wk-form4_1765405243.xml · nonDerivative · entry 3

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,860

F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $30.485 to $31.305 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-25-000166 · wk-form4_1765405243.xml · nonDerivative · entry 2

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,108

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-25-000166 · wk-form4_1765405243.xml · nonDerivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,248

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-25-000101 · wk-form4_1750450217.xml · derivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,150

Underlying: Common Stock · 14,150 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

F2 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

SEC source: 0000805928-25-000080 · wk-form4_1749673350.xml · derivative · entry 5

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,248

Underlying: Common Stock · 4,000 shares

Expires 2034-06-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Options vested on the first anniversary of the grant date, which was June 6, 2024.

SEC source: 0000805928-25-000080 · wk-form4_1749673350.xml · derivative · entry 4

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,586 shares

Expires 2033-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Options vested on the first anniversary of the grant date, which was September 1, 2023.

SEC source: 0000805928-25-000080 · wk-form4_1749673350.xml · nonDerivative · entry 3

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold on June 10, 2025 in multiple transactions at prices ranging from $10.69 to $10.83 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000805928-25-000080 · wk-form4_1749673350.xml · nonDerivative · entry 2

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,931

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-25-000080 · wk-form4_1749673350.xml · nonDerivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,931

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-25-000072 · wk-form4_1748032349.xml · derivative · entry 4

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,586

Underlying: Common Stock · 12,850 shares

Expires 2033-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Options vested on the first anniversary of the grant date, which was September 1, 2023.

SEC source: 0000805928-25-000072 · wk-form4_1748032349.xml · nonDerivative · entry 3

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,345

F2 · price: The price reported in Column 4 is a weighted average price. These shares of common stock were sold in multiple transactions at prices ranging from $11.15 to $11.29, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000805928-25-000072 · wk-form4_1748032349.xml · nonDerivative · entry 2

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,557

F1 · price: The price reported in Column 4 is a weighted average price. These shares of common stock were sold in multiple transactions at prices ranging from $11.15 to $11.31, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0000805928-25-000072 · wk-form4_1748032349.xml · nonDerivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,407

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000805928-25-000070 · wk-form4_1748031148.xml · nonDerivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,557

SEC source: 0000805928-24-000116 · wk-form4_1725488740.xml · derivative · entry 2

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,904 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F3 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date.

F3 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date.

SEC source: 0000805928-24-000116 · wk-form4_1725488740.xml · nonDerivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,557

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This reflects the number of restricted stock units that vested on September 1, 2024.

SEC source: 0000805928-25-000004 · wk-form5_1736206828.xml · nonDerivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,082

F1 · date: Discloses an inadverent failure to report a purchase by the individual made in 2024.

SEC source: 0000805928-24-000091 · wk-form4_1718057504.xml · derivative · entry 2

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,248

Underlying: Common Stock · 18,248 shares

Expires 2034-06-06

F2 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 6, 2025, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-24-000091 · wk-form4_1718057504.xml · nonDerivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,653

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

SEC source: 0000805928-23-000118 · wf-form4_169408271704129.xml · derivative · entry 2

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,904

Underlying: Common Stock · 11,904 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units which shares will be delivered to the reporting person upon vesting.

F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units which shares will be delivered to the reporting person upon vesting.

SEC source: 0000805928-23-000118 · wf-form4_169408271704129.xml · derivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,436

Underlying: Common Stock · 20,436 shares

Expires 2033-09-01

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on September 1, 2024, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units which shares will be delivered to the reporting person upon vesting.

SEC source: 0000805928-22-000127 · wf-form4_167114569833528.xml · derivative · entry 1

TYNDALL JOSEPH A. · CIK 0001955281 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,171

Underlying: Common Stock · 43,171 shares

Expires 2032-12-13

F1 · derivative.exercise_date: Option grant for joining the Issuer's Board of Directors. Options vest in three equal annual installments on the annual anniversary of the grant date with the first vesting date occurring on December 13, 2023.